Citations

Showing 10 of 108083 citations.

Evaluation of Perioperative Versus Extended Courses of Antibiotic Prophylaxis After Immediate Implant-Based Breast Reconstruction
Zhang, Casey , Moroni, Elizabeth A. , Bustos, Samyd S. , Cruz, Carolyn De La , Gimbel, Michael L. , Nguyen, Vu T. , Bustos, S S

Mayo Clinic

Annals of Plastic Surgery | February 22, 2023 | Volume: 90 | Issue: 6S | Pages: S593-S597

10.1097/sap.0000000000003473 | PMID 37399483 Get It

Background Immediate implant-based breast reconstruction (IIBR) is the most commonly used method in breast reconstruction in the United States. However, postoperative surgical site infections (SSIs) can cause devastating reconstructive failure. This study evaluates the use of perioperative versus extended courses of antibiotic prophylaxis after IIBR for the prevention of SSI. Methods This is a single-institution retrospective study of patients who underwent IIBR between June 2018 and April 2020. Detailed demographic and clinical information was collected. Patients were divided into subgroups based on antibiotic prophylaxis regimen: group 1 consisted of patients who received 24 hours of perioperative antibiotics and group 2 consisted of patients who received ≥7 days of antibiotics. Statistical analyses were conducted using SPSSv26.0 with P ≤ 0.05 considered statistically significant. Results A total of 169 patients (285 breasts) who underwent IIBR were included. The mean age was 52.4 ± 10.2 years, and the mean body mass index (BMI) was 26.8 ± 5.7 kg/m2. Twenty-five percent of patients (25.6%) underwent nipple-sparing mastectomy, 69.1% skin-sparing mastectomy, and 5.3% total mastectomy. The implant was placed in the prepectoral, subpectoral, and dual planes in 16.7%, 19.2%, and 64.1% cases, respectively. Acellular dermal matrix was used in 78.7% of cases. A total of 42.0% of patients received 24-hour prophylaxis (group 1), and 58.0% of patients received extended prophylaxis (group 2). Twenty-five infections (14.8%) were identified, of which 9 (5.3%) resulted in reconstructive failure. In bivariate analyses, no significant difference was found between groups in rates of infection (P = 0.273), reconstructive failure (P = 0.653), and seroma (P = 0.125). There was a difference in hematoma rates between groups (P = 0.046). Interestingly, in patients who received only perioperative antibiotics, infection rates were significantly higher in those with BMI ≥ 25 (25.6% vs 7.1%, P = 0.050). There was no difference in overweight patients who received extended antibiotics (16.4% vs 7.0%, P = 0.160). Conclusions Our data demonstrate no statistical difference in infection rates between perioperative and extended antibiotics. This suggests that the efficacies of current prophylaxis regimens are largely similar, with choice of regimen based on surgeon preference and patient-specific considerations. Infection rates in patients who received perioperative prophylaxis and were overweight were significantly higher, suggesting that BMI should be taken into consideration when choosing a prophylaxis regimen.
The Brief Case: the Cryptic Cryptococcus
Misra, Anisha , Yetmar, Zachary A. , Milone, Amber A., Ruefthaler, Lydia A., Wengenack, Nancy L. , Vergidis, Paschalis , Theel, Elitza S. , Yetmar, Zachary A , Vergidis, Paschalis

Mayo Clinic

Journal of Clinical Microbiology | February 22, 2023 | Volume: 61 | Issue: 2 | Pages: No page available

10.1128/jcm.00548-22 | PMID 36840562 Get It

Video-Based (Livestream) and In-Person Continuing Professional Development: Participant and Course Features Associated With Choice
Cook, David A. , Pendl, Aaron K., Pankratz, V. Shane , Pankratz, V. Shane

Mayo Clinic

Academic Medicine | February 22, 2023 | Volume: 98 | Issue: 8 | Pages: 949-957

10.1097/acm.0000000000005174 | PMID 36812047 Get It

Abstract Purpose Information on factors influencing learner choice between in-person and video-based continuing professional development (CPD) would help course leaders with planning and implementation. This study aimed to investigate how registration patterns differ between in-person and video-based offerings for the same CPD course. Method The authors obtained data from 55 CPD courses offered in-person (at various U.S. locations) and via livestreamed video, January 2020 to April 2022. Participants included physicians, advanced practice providers, allied health professionals, nurses, and pharmacists. Registration rates were compared by participant and course features including professional role, age, country of residence, distance to and perceived desirability of the in-person destination, and timing of registration. Results Analyses included 11,072 registrations, of which 4,336 (39.2%) were for video-based learning. There was significant heterogeneity in video-based registrations across courses, ranging 14.3% to 71.4%. Multivariable analysis showed higher video-based registrations for advanced practice providers (vs physicians; adjusted odds ratio [AOR] 1.80 [99% confidence interval, 1.55–2.10]), non-U.S. residents (AOR 3.26 [1.18–9.01]), longer distance (AOR 1.19 [1.16–1.23] for each doubling of distance), and courses in July–September 2021 (vs January–April 2022; AOR 1.59 [1.24–2.02]); video-based registrations were lower for current or former employees or trainees of our institution (AOR 0.53 [0.45–0.61]), destinations of moderate or high desirability (vs low; AOR 0.42 [0.34–0.51] and 0.44 [0.33–0.58], respectively), and early registration (AOR 0.67 [0.64–0.69] for each doubling of days between registration and course start). There was no significant difference by age (AOR 0.92 [0.82–1.05] for participants > 46 years old vs younger participants). The multivariable model correctly predicted actual registration 78.5% of the time. Conclusions Video-based livestreamed CPD is popular (chosen by nearly 40% of participants), although choices varied widely by course. Professional role, institutional affiliation, distance traveled, location desirability, and registration timing have small but statistically significant associations with choice of video-based vs in-person CPD.
Association Between Survival and Metastatic Site in Mismatch Repair–Deficient Metastatic Colorectal Cancer Treated With First-line Pembrolizumab
Jones, Jeremy , Shi, Qian , Ticku, Jonathan, Saberzadeh-Ardestani, Bahar , Jones, Jeremy C., Hubbard, Joleen M. , Sonbol, Mohamad Bassam , Shi, Qian , Jones, Jeremy C , McWilliams, Robert R. , Hálfdánarson, Þorvarður R. , Jin, Zhaohui , Sinicrope, Frank A.

Mayo Clinic

JAMA Network Open | February 22, 2023 | Volume: 6 | Issue: 2 | Pages: e230400

10.1001/jamanetworkopen.2023.0400 | PMID 36811859 Get It

Importance Metastatic colorectal cancer (mCRC) with deficient DNA mismatch repair (dMMR) shows frequent and durable responses to programmed cell death 1 blockade. While most of these tumors are sporadic and observed in older patients, first-line pembrolizumab data are limited to findings from the KEYNOTE-177 trial (A Phase III Study of Pembrolizumab [MK-3475] vs Chemotherapy in Microsatellite Instability-High [MSI-H] or Mismatch Repair Deficient [dMMR] Stage IV Colorectal Carcinoma). Objective To investigate outcome with first-line pembrolizumab monotherapy in mostly older patients with dMMR mCRC at a multisite clinical practice. Design, Setting, and Participants This cohort study included consecutive patients with dMMR mCRC who received pembrolizumab monotherapy between April 1, 2015, and January 1, 2022, at Mayo Clinic sites and the Mayo Clinic Health System. Patients were identified from review of electronic health records at the sites, which included the evaluation of digitized radiologic imaging studies. Intervention Patients with dMMR mCRC received first-line pembrolizumab, 200 mg, every 3 weeks. Main Outcomes and Measures The primary study end point was progression-free survival (PFS), which was analyzed using the Kaplan-Meier method and a multivariable stepwise Cox proportional hazards regression model. Clinicopathological features, including metastatic site and molecular data ( BRAF V600E and KRAS ), were also analyzed along with tumor response rate, which was determined using Response Evaluation Criteria in Solid Tumors, version 1.1. Results The study cohort included 41 patients (median [IQR] age at treatment initiation, 81 [76-86] years; 29 females [71%]) with dMMR mCRC. Of these patients, 30 (79%) had the BRAF V600E variant and 32 (80%) were classified as having sporadic tumors. Median (range) follow-up was 23 (3-89) months. Median (IQR) number of treatment cycles was 9 (4-20). Overall response rate was 49% (20 of 41 patients), including 13 patients (32%) with complete responses and 7 (17%) with partial responses. Median (IQR) PFS was 21 (95% CI, 6-39) months. Liver as a site of metastasis was associated with significantly poorer PFS vs nonliver metastasis (adjusted hazard ratio, 3.40; 95% CI, 1.27-9.13; adjusted P = .01). Complete and partial responses were observed in 3 patients (21%) with liver metastasis vs 17 patients (63%) with nonliver metastases. Treatment-related grade 3 or 4 adverse events were observed in 8 patients (20%), 2 of whom discontinued therapy; there was 1 treatment-related death. Conclusions and Relevance This cohort study found a clinically significant prolongation of survival in older patients with dMMR mCRC who were treated with first-line pembrolizumab in routine clinical practice. Furthermore, liver vs nonliver metastasis was associated with poorer survival in this patient population, which suggests that the metastatic site has implications for survival outcome.
Familial Hypercholesterolemia in the Electronic Medical Records and Genomics Network: Prevalence, Penetrance, Cardiovascular Risk, and Outcomes After Return of Results
Dikilitas, Ozan , Sherafati, Alborz , Saadatagah, Seyedmohammad , Kochan, David C., Anderson, Katherine , Chung, Wendy K. , Hebbring, Scott J. , Salvati, Zachary , Sharp, Richard R. , Sturm, Amy C. , Gibbs, Richard A. , Rowley, Robb , Linder, Jodell E. , Perez, Emma , Peterson, Josh F. , Jarvik, Gail P. , Roden, Dan M. , Manolio, Teri A. , Satterfield, Benjamin A , Anderson, Katherine C , Chung, Wendy K. , Salvati, Zachary M , Sharp, Richard R , Sturm, Amy C , Rowley, Robb , Venner, Eric , Linder, Jodell E , Jones, Laney K , Peterson, Josh F , Jarvik, Gail P , Rehm, Heidi L , Zouk, Hana , Roden, Dan M. , Williams, Marc S , Manolio, Teri A , Kullo, Iftikhar J , Dikilitas, Ozan , Satterfield, Benjamin A. , Venner, Eric , Rehm, Heidi L. , Kullo, Iftikhar J.

Mayo Clinic

Circulation: Genomic and Precision Medicine | February 22, 2023 | Volume: 16 | Issue: 2 | Pages: No page available

10.1161/circgen.122.003816 | PMID 37071725 Get It

Background: The implications of secondary findings detected in large-scale sequencing projects remain uncertain. We assessed prevalence and penetrance of pathogenic familial hypercholesterolemia (FH) variants, their association with coronary heart disease (CHD), and 1-year outcomes following return of results in phase III of the electronic medical records and genomics network. Methods: Adult participants (n=18 544) at 7 sites were enrolled in a prospective cohort study to assess the clinical impact of returning results from targeted sequencing of 68 actionable genes, including LDLR , APOB , and PCSK9 . FH variant prevalence and penetrance (defined as low-density lipoprotein cholesterol >155 mg/dL) were estimated after excluding participants enrolled on the basis of hypercholesterolemia. Multivariable logistic regression was used to estimate the odds of CHD compared to age- and sex-matched controls without FH-associated variants. Process (eg, referral to a specialist or ordering new tests), intermediate (eg, new diagnosis of FH), and clinical (eg, treatment modification) outcomes within 1 year after return of results were ascertained by electronic health record review. Results: The prevalence of FH-associated pathogenic variants was 1 in 188 (69 of 13,019 unselected participants). Penetrance was 87.5%. The presence of an FH variant was associated with CHD (odds ratio, 3.02 [2.00–4.53]) and premature CHD (odds ratio, 3.68 [2.34–5.78]). At least 1 outcome occurred in 92% of participants; 44% received a new diagnosis of FH and 26% had treatment modified following return of results. Conclusions: In a multisite cohort of electronic health record–linked biobanks, monogenic FH was prevalent, penetrant, and associated with presence of CHD. Nearly half of participants with an FH-associated variant received a new diagnosis of FH and a quarter had treatment modified after return of results. These results highlight the potential utility of sequencing electronic health record–linked biobanks to detect FH.
Elucidation of ALG10B as a Novel Long-QT Syndrome–Susceptibility Gene
Zhou, Wei , Ye, Dan , Tester, David J. , Bains, Sahej , Giudicessi, John R. , Haglund-Turnquist, Carla , Orland, Kate M. , January, Craig T., Eckhardt, Lee L. , Maginot, Kathleen R., Ackerman, Michael J. , Haglund-Turnquist, Carla M , Eckhardt, Lee L , Bains, Sahej , Ye, Dan

Mayo Clinic

Circulation: Genomic and Precision Medicine | February 22, 2023 | Volume: 16 | Issue: 2 | Pages: No page available

10.1161/circgen.122.003726 | PMID 37071726 Get It

Background: Long-QT syndrome (LQTS) is characterized by QT prolongation and increased risk for syncope, seizures, and sudden cardiac death. The majority of LQTS stems from pathogenic mutations in KCNQ1 , KCNH2 , or SCN5A . However, ≈10% of patients with LQTS remain genetically elusive. We utilized genome sequencing to identify a novel LQTS genetic substrate in a multigenerational genotype-negative LQTS pedigree. Methods: Genome sequencing was performed on 5 affected family members. Only rare nonsynonymous variants present in all affected family members were considered. The candidate variant was characterized functionally in patient-derived induced pluripotent stem cell and gene-edited, variant corrected, isogenic control induced pluripotent stem cell–derived cardiomyocytes. Results: A missense variant (p.G6S) was identified in ALG10B -encoded α-1,2-glucosyltransferase B protein. ALG10B (alpha-1,2-glucosyltransferase B protein) is a known interacting protein of KCNH2 -encoded K v 11.1 (HERG [human Ether-à-go-go–related gene]). Compared with isogenic control, ALG10B-p.G6S induced pluripotent stem cell–derived cardiomyocytes showed (1) decreased protein expression of ALG10B (p.G6S, 0.7±0.18, n=8 versus control, 1.25±0.16, n=9; P <0.05), (2) significant retention of HERG in the endoplasmic reticulum ( P <0.0005), and (3) a significantly prolonged action potential duration confirmed by both patch clamp (p.G6S, 531.1±38.3 ms, n=15 versus control, 324.1±21.8 ms, n=13; P <0.001) and multielectrode assay ( P <0.0001). Lumacaftor—a compound known to rescue HERG trafficking—shortened the pathologically prolonged action potential duration of ALG10B-p.G6S induced pluripotent stem cell–derived cardiomyocytes by 10.6% (n=31 electrodes; P <0.001). Conclusions: Here, we demonstrate that ALG10B-p.G6S downregulates ALG10B, resulting in defective HERG trafficking and action potential duration prolongation. Therefore, ALG10B is a novel LQTS-susceptibility gene underlying the LQTS phenotype observed in a multigenerational pedigree. ALG10B mutation analysis may be warranted, especially in genotype-negative patients with an LQT2-like phenotype.
Improved cochlear implant electrode localization using coregistration of pre‐ and postoperative CT
Farnsworth, Paul J. , Benson, John C. , Nassiri, Ashley M. , Carlson, Matthew L. , Larson, Nicholas B. , Lane, John I. , Benson, John , Larson, Nicholas B , Farnsworth, Paul

Mayo Clinic

Journal of Neuroimaging | February 22, 2023 | Volume: 33 | Issue: 3 | Pages: 387-392

10.1111/jon.13094 | PMID 36811338 Get It

Abstract Background and Purpose Artifact from cochlear implant electrodes degrades image resolution on CT. Here, we describe the use of coregistered pre‐ and postoperative CT images to reduce metallic artifact from the electrodes to assess its position more accurately within the cochlear lumen. Methods Pre‐ and postoperative CTs were reviewed after coregistration/overlay of both exams. Images were evaluated by two neuroradiologists for scalar location of electrodes tip (± scalar translocation), tip fold over, and angular depth of insertion. Results Thirty‐four patients were included in the final cohort. Transscalar migration was present in three (8.8%) cases (one case demonstrated tip fold over), with initial disagreement regarding transscalar migration in 1 out of 34 patients (2.9%). Agreement regarding depth of insertion was present in 31 (91.1%) cases. Five‐point Likert scales were used to compare the ability to resolve the proximity of electrodes to the lateral/outer cochlear wall without and with overlay, which is a qualitative measure of artifact from the array. Likert scores showed definitive benefit of metal artifact reduction using overlayed images with an average score of 4.34. Conclusion This study demonstrates a novel technique of using fused coregistration of pre‐ and postoperative CTs for the purpose of artifact reduction/electrode localization. It is anticipated that this technique will permit more accurate localization of the electrodes for improvement in surgical technique and electrode array design.
Healthcare Resource Utilization in Patients with Newly Diagnosed Atrial Fibrillation: A Global Analysis from the GARFIELD-AF Registry
Mantovani, LG , Cozzolino, Paolo , Ferrara, Pietro , Virdone, Saverio , Camm, A. John , Verheugt, Freek W.A. , Bassand, Jean‐Pierre , Turpie, Alexander G.G., Hacke, Werner, Kayani, Gloria , Goldhaber, Samuel Z. , Goto, Shinya , Pieper, Karen S. , Haas, Sylvia , Eickels, Martin van, Kakkar, Ajay K. , Investigators, on behalf of the GARFIELD-AF, Verheugt, Freek W A , Gersh, Bernard J. , Fox, Keith A.A. , Investigators, on behalf of the GARFIELD-AF

Mayo Clinic

Healthcare | February 22, 2023 | Volume: 11 | Issue: 5 | Pages: 638

10.3390/healthcare11050638 | PMID 36900643 Get It

The management of atrial fibrillation (AF), the most common sustained arrhythmia, impacts healthcare resource utilization (HCRU). This study aims to estimate global resource use in AF patients, using the GARFIELD-AF registry. A prospective cohort study was conducted to characterize HCRU in AF patients enrolled in sequential cohorts from 2012 to 2016 in 35 countries. Components of HCRU studied were hospital admissions, outpatient care visits, and diagnostic and interventional procedures occurring during follow-up. AF-related HCRU was reported as the percentage of patients demonstrating at least one event and was quantified as rate-per-patient-per-year (PPPY) over time. A total of 49,574 patients was analyzed, having an overall median follow-up of 719 days. Almost all patients (99.5%) had at least one outpatient care visit, while hospital admissions were the second most frequent medical contact, with similar proportions in North America (37.5%) and Europe (37.2%), and slightly higher in the other GARFIELD-AF countries (42.0%; namely Australia, Egypt, and South Africa). Asia and Latin America showed lower percentages of hospitalizations, outpatient care visits, and diagnostic and interventional procedures. Analyses of GARFIELD-AF highlighted the vast AF-related HCRU, underlying significant geographical differences in the type, quantity, and frequency of AF-related HCRU. These differences were likely attributable to health service availability and differing models of care.
Are we improving? Temporal trends in outcomes for mechanical thrombectomy for stroke: A systematic review and meta-analysis of randomized trials
Kobeissi, Hassan , Ghozy, Sherief , Bilgin, Cem , Kadirvel, Ramanathan , Brinjikji, Waleed , Kallmes, David F. , Ghozy, Sherief , Kobeissi, Hassan , Bilgin, Cem

Mayo Clinic

Interventional Neuroradiology | February 22, 2023 | Volume: 32 | Issue: 3 | Pages: 685-690

10.1177/15910199231158938 | PMID 36924270 Get It

Background In 2015, mechanical thrombectomy (MT) was deemed the standard of care for acute ischemic stroke (AIS) in the anterior circulation due to large vessel occlusion (LVO). To determine if outcomes in patients treated with MT have changed, we conducted a systematic review and meta-analysis of published randomized controlled trials (RCTs). Methods A systematic literature review of the English language literature was conducted using PubMed. We included RCTs that focused on patients with AIS treated with MT. The primary outcome of interest was good functional outcome defined as modified Rankin Scale (mRS) 0–2 at 90 days. Safety outcomes included rates of symptomatic intracranial hemorrhage (sICH) and mortality at 90 days. Using Joinpoint Regression Analysis Program, we calculated the average annual percent change (AAPC) for the outcomes of interest. Results We included 23 RCTs with 5784 patients. The years of mid-enrollment among the included RCTs ranged from 2012–2020. There was an AAPC of +3.82% between 2012 and 2020 (95% CI 0.4 to 7.3; P -value = 0.033) in rates of good functional outcome. There was an AAPC of +6.98% between 2012 and 2020 (95% CI 0.5 to 13.9; P -value = 0.039) in rates of sICH. There was an AAPC of −0.49% between 2012 and 2020 (95% CI −4.4 to 3.5; P -value = 0.77) in rates of mortality. Conclusion Between 2012 and 2020, rates of good functional outcome and sICH increased, while rates of mortality remained consistent in RCTs investigating MT for AIS. Multiple factors likely influenced our results, including increased use of MT and utilization of adjunctive therapies alongside MT.
DTRMWXHS ‐12, a novel Bruton tyrosine kinase inhibitor, in combination with everolimus and pomalidomide in patients with relapsed/refractory lymphomas: An open‐label, multicenter, phase 1a/1b study
Huntington, Scott F. , Ding, Wei , Koehler, Amber B. , Brander, Danielle M. , Leis, José F., Iqbal, Madiha , Kearney, Albert S., McKinlay, Timothy P., Gui, Min, Mato, Anthony R. , Ding, Wei , Rosenthal, Allison , Iqbal, Madiha , Schuster, Stephen J. , Tun, Han W. , Moustafa, Muhamad Alhaj , He, Wei , McKinlay, Tim, Gui, Min

Mayo Clinic

American Journal of Hematology | February 22, 2023 | Volume: 98 | Issue: 5 | Pages: 739-749

10.1002/ajh.26888 | PMID 36810799 Get It

Abstract Preclinical studies have shown augmented activity when combining Bruton tyrosine kinase inhibitors (BTKi) with inhibitors of mammalian target of rapamycin (mTOR) and immunomodulatory agents (IMiD). We conducted a phase 1, open‐label study at five centers in USA to evaluate the safety of triplet BTKi/mTOR/IMiD therapy. Eligible patients were adults aged 18 years or older with relapsed/refractory CLL, B cell NHL, or Hodgkin lymphoma. Our dose escalation study used an accelerated titration design and moved sequentially from single agent BTKi (DTRMWXHS‐12), doublet (DTRMWXHS‐12 + everolimus), and then to triplet therapy (DTRMWXHS‐12 + everolimus + pomalidomide). All drugs were dosed once daily on days 1–21 of each 28‐day cycle. The primary goal was to establish the recommended phase 2 dose of the triplet combination. Between September 27, 2016, and July 24, 2019, a total of 32 patients with a median age of 70 years (range 46 to 94 years) were enrolled. No MTD was identified for monotherapy and the doublet combination. The MTD for the triplet combination was determined to be DTRMWXHS‐12 200 mg + everolimus 5 mg + pomalidomide 2 mg. Responses across all studied cohorts were seen in 13 of 32 (41.9%). Combining DTRMWXHS‐12 with everolimus and pomalidomide is tolerable and shows clinical activity. Additional trials could confirm benefit of this all‐oral combination therapy for relapsed/refractory lymphomas.